Mesoblast stock highlights US$115 million FY2026 revenue
Published on 11/17/2026 at 20:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCommercial progress and pipeline timing
- Mesoblast entered a five-year US$125.0 million non-dilutive credit facility and retired two higher-cost facilities.
- The Phase 3 chronic low back pain trial has completed treatment for 350 patients, with a readout targeted for the second half of calendar 2027.
- A registration trial is enrolling adults with severe steroid-refractory acute graft-versus-host disease, while RYONCIL expansion remains a central commercial priority.
Mesoblast reported US$115 million in fiscal 2026 net revenue and gross profit on total sales of US$110 million, excluding amortization expense, in materials filed on Monday, November 16, 2026. The company also announced a new five-year, US$125.0 million non-dilutive credit facility that consolidates and retires two higher-cost facilities. The figures and transaction details appear in Mesoblast's SEC Form 6-K.
Mesoblast stock traded at 1.10 euros on Lang & Schwarz at 20:18 CET on Tuesday, November 17, 2026.
Commercial progress and clinical milestones
The company described fiscal 2026 as its first full year after the U.S. launch of RYONCIL, its treatment for pediatric steroid-refractory acute graft-versus-host disease. Mesoblast is pursuing a label expansion into adults with the same condition and said the registration trial is enrolling Grade III/IV patients at U.S. centers.
Mesoblast also said 350 patients had completed treatment in its Phase 3 chronic low back pain trial for rexlemestrocel-L. The company targets a readout in the second half of calendar 2027, followed by a potential biologics license application. In cardiopulmonary programs, Mesoblast said the FDA had confirmed that a filing may proceed for patients with left ventricular assist devices and life-threatening major gastrointestinal bleeding.
Financing supports expansion
The new credit facility is intended to support commercial growth and late-stage development while replacing two more expensive facilities. Mesoblast highlighted RYONCIL sales expansion, adult acute graft-versus-host disease and late-stage programs in chronic low back pain and heart failure as its principal value-creation priorities.
The company is listed on the Australian Securities Exchange and Nasdaq. The S&P/ASX 200 provides the relevant market backdrop for its primary Australian listing.
Mesoblast's next milestones are tied to RYONCIL's adult development program, the chronic low back pain readout and regulatory work in cardiopulmonary indications.
Mesoblast at a glance
- Company: Mesoblast Limited
- Tickers: ASX: MSB; Nasdaq: MESO
- Primary listing: Australian Securities Exchange
- Lang & Schwarz quote: 1.10 euros at 20:18 CET on November 17, 2026
- Fiscal 2026 net revenue: US$115 million
- New credit facility: US$125.0 million over five years
